Recombinant platelet factor 4 data

RGEN (Cambridge, Mass.) reported interim results in 11 patients enrolled in its Phase II trial, showing an anti-tumor response rate of 36 percent, and a decline in size of injected lesions of 72 percent a month after starting treatment.

Patients received 2.5 mg or 5 mg of rPF4 three times a week for eight weeks, and the dosing continued if a response occurred. ...